Back grey_arrow_rt.gif
 
Archived NATAP Articles from July 2002
 
null.gif
 
 
  1. FTC: a 3TC like drug for HIV - (7/31/02)

  2.  
  3. Intermittent Viremia Increases Risk 3 Times for Viral Failure and Impairs CD4 Response - (7/30/02)

  4.  
  5. Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash - (7/30/02)

  6.  
  7. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. - (7/29/02)

  8.  
  9. Barcelona - Metabolic Complications of HIV and its Therapies: What Did We Learn in Barcelona? - (7/25/02)

  10.  
  11. High Prevalence of Osteonecrosis of the Femoral Head in HIV-Infected Adults - (7/24/02)

  12.  
  13. New Information on Liver & Kidney Transplants in HIV+ Patients - (7/24/02)

  14.  
  15. Drug Resistance Workshop - Summary Report on the Resistance Workshop -Written by David Margolis, MD, University of Texas Southwestern Medical Center - (7/24/02)

  16.  
  17. Studies Find Low-Level HIV Drug Resistance During Therapy and Interruptions; Does 3 month Interruption Help or Harm? - (7/24/02)

  18.  
  19. New Drugs: TMC114 (PI) and TMC125 (NNRTI) - (7/24/02)

  20.  
  21. Barcelona - Liver Transplants Successful in HIV+ - (7/18/02)

  22.  
  23. Barcelona - Tenofovir and DDI EC Interactions: TDF raises ddI levels 50-70% - (7/18/02)

  24.  
  25. Barcelona - HAART Did Not Prevent or Reduce Rates of Anal Intraepithelial Neoplasia; Screening Recommended For All - (7/17/02)

  26.  
  27. Barcelona - Anal Sex Increases Risk For Heterosexual HIV Transmission - (7/17/02)

  28.  
  29. Barcelona - A Lipodystrophy Reformation? - (7/16/02)

  30.  
  31. Barcelona - Nevirapine Hepatotoxicity - (7/16/02)

  32.  
  33. Barcelona - FDA GRANTS PRIORITY REVIEW TO PEGASYS (peginterferon alfa-2a) AND RIBAVIRIN COMBINATION FOR TREATMENT OF HEPATITIS C - (7/16/02)

  34.  
  35. Barcelona - Short & Long Term Adherence/Education Programs - (7/16/02)

  36.  
  37. Barcelona - Once Daily - d4T, AZT - (7/15/02)

  38.  
  39. Barcelona - HGH for AIDS Related Wasting - (7/15/02)

  40.  
  41. Barcelona - Does Liver Disease Improve for HCV Therapy Nonresponders? - (7/15/02)

  42.  
  43. Barcelona - Human Growth Hormone for Lipodystrophy: daily vs alternate day dosing - (7/15/02)

  44.  
  45. Barcelona - GUESS Study: inconsistencies by experts in interpreting resistance test results - (7/15/02)

  46.  
  47. Barcelona - Kaletra in Women - (7/15/02)

  48.  
  49. Barcelona - New Integrase Inhibitor, S-1360 - (7/12/02)

  50.  
  51. Barcelona - GIGHAART: 8-week Treatment Interruption Improves Viral Response in Deep Salvage - (7/12/02)

  52.  
  53. Barcelona - Tenofovir vs d4T: 48 Week Study Results in Treatment Naïve - (7/12/02)

  54.  
  55. Barcelona - PegIntron + Ribavirin in HIV/HCV Coinfected Patients - (7/11/02)

  56.  
  57. Barcelona - Body Changes: indinavir vs nevirapine vs 3TC, plus d4T/ddI. Protease Inhibitors Appear to Increase Risk For Premature Heart Disease - (7/11/02)

  58.  
  59. Barcelona - Lipoatrophy Didn't Improve: switch to PI-Sparing - (7/10/02)

  60.  
  61. HIV Activist Jules Levin Comments on T-20 Drug Study - (07/10/02)

  62.  
  63. Barcelona - Kaletra Did Not Result in Methadone Withdrawal - (7/10/02)

  64.  
  65. DDW - Review of Oral Presentations and Posters presented at DDW May 19-20 Written by Written by Andrew Talal, MD, NY Hospital-Cornell Medical College, Dept of GI & Hepatology - (7/9/02)

  66.  
  67. Barcelona - Kaletra Once Daily; Efavirenz in Patients with Highly Advanced HIV - (7/9/02)

  68.  
  69. Barcelona - Tenofovir vs D4T 48 Week Study Results: cholesterol, triglycerides - (7/9/02)

  70.  
  71. New HIV Drugs / Hep C: quicker HCV progression nin coinfection; sumptomatic hyperlactatemia in coinfected patients taking RBV; PegIntron/RBV in coinfected - (7/8/02)

  72.  
  73. Barcelona - T-20: new class of drug about to enter market; fusion inhibitor - (7/8/02)

  74.  
  75. Opening Ceremony at Barcelona - (7/8/02)

  76.  
  77. Drug Resistance Workshop - Resistance Patterns - (7/8/02)

  78.  
  79. Drug Resistance Workshop - Mutation Score for Tenofovir: guidance in using tenofovir (Viread) - (7/8/02)

  80.  
  81. Drug Resistance Workshop - Brief Summary Highlights From the 11th Resistance Workshop - (7/8/02)

  82.  
  83. Drug Resistance Workshop - Reducing Viral load to Very Low and Keeping CD4s High Despite Viral Load Failure - (7/8/02)

  84.  
  85. 3TC Once Daily Approved - (07/3/02)

  86.  
  87. Drug Resistance Workshop - BRAND NEW DRUGS FOR HIV - (7/3/02)

  88.